Phase 1 Clinical Trial Data Indicate IGCÃ’s THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer’s Patients December 2, 2021 Read More »
IGC Completes its Phase 1 Clinical Trial on Alzheimer’s Patients, Reports Safety and Tolerability September 8, 2021 Read More »
IGC Completes the Final Cohort of its Phase 1 Clinical Trial on Alzheimer’s Patients June 24, 2021 Read More »
IGC Announces Issuance of Patent for the Treatment of Alzheimer’s Disease Using THC June 22, 2021 Read More »
IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients June 9, 2021 Read More »
IGC Completes Cohort 1 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients May 14, 2021 Read More »
IGC Receives Another Patent for a Cannabinoid-Based Cream for Treating Pain March 8, 2021 Read More »
